Symbiotec Pharmalab Q2FY27 PAT Up 169% to ₹52 Cr

Symbiotec Pharmalab Limited announced its unaudited financial results for Q2 and H1 FY27. The company reported a significant 169% year-on-year growth in consolidated Profit After Tax (PAT) to ₹52 crore for Q2 FY27, compared to ₹19 crore in Q2 FY26. Consolidated revenues reached ₹53 crore, driven by milestone-based revenue from Complex Injectables. The API business showed steady growth of 11% in H1 FY27 with gross margins above 60% and EBITDA margins around 30%. Key operational highlights include successful completion of EUGMP and USFDA audits for its plants. The company also advanced its Complex Injectables and CDMO businesses, with a licensing agreement for DCV products in the US and a take-or-pay agreement in the alternative protein space. Total gross capex is estimated at ₹1,672 crore by end FY27, with ₹1,000 crore invested in new revenue-generating businesses.